ライフサイエンスコーパス: patent ductus arteriosus

1 s of death or bronchopulmonary dysplasia and patent ductus arteriosus.

2 encodes a Notch ligand, die postnatally from patent ductus arteriosus.

3 the use of indomethacin to treat symptomatic patent ductus arteriosus.

4 treatment, despite success in closure of the patent ductus arteriosus.

5 anomalous lobar pulmonary veins or a silent patent ductus arteriosus.

6 those neonates without clinically suspected patent ductus arteriosus.

7 y be of predictive value for the presence of patent ductus arteriosus.

8 uctus arteriosus, with a 92% specificity for patent ductus arteriosus.

9 established techniques for coil occlusion of patent ductus arteriosus.

10 ductal shunting following coil occlusion of patent ductus arteriosus.

11 red with those of 14 preterm infants without patent ductus arteriosus.

12 ociated with intraventricular hemorrhage and patent ductus arteriosus.

13 ch pulmonary artery stenoses, and persistent patent ductus arteriosus.

14 7, 47%), atrial septal defects (20/47, 43%), patent ductus arteriosus (16/47, 34%), persistent left s

15 al CHD, 4 with atrial septal defects, 2 with patent ductus arteriosus, 2 with tetralogy of Fallot, an

16 rvention group than in the placebo group had patent ductus arteriosus (adjusted relative risk, 1.65;

17 In other areas, such as patent ductus arteriosus and atrioventricular septal def

18 ent with epilepsy and other signs, including patent ductus arteriosus and coagulopathy, while hemizyg

19 Patent ductus arteriosus and coarctation of aorta occurr

20 11 (c.4599+1delG) was identified in familial patent ductus arteriosus and found to disrupt normal spl

21 us arteriosus to close after birth is termed patent ductus arteriosus and is one of the most common c

22 f particular interest because it also causes patent ductus arteriosus and moyamoya disease.

23 studies describing an association between a patent ductus arteriosus and the development of morbidit

24 A concomitant cardiac lesion, for example, patent ductus arteriosus, and aortic cross-clamp time we

25 of patients with interatrial communications, patent ductus arteriosus, and pulmonary artery stenosis

26 fied young age at angioplasty, presence of a patent ductus arteriosus, and the diameters of the aorti

27 ds ratio [AOR], 0.81; 95% CI, 0.67-0.98) and patent ductus arteriosus (AOR, 0.74; 95% CI, 0.62-0.89).

28 tal defect (aORs ranging from 1.29 to 2.17), patent ductus arteriosus [aORs = 1.54, 1.63; 95% confide

29 including the aorta, pulmonary arteries, and patent ductus arteriosus, are each amenable to transcath

30 hose neonates subsequently diagnosed to have patent ductus arteriosus, based on clinical suspicion an

31 premature infants with than in those without patent ductus arteriosus because afterload is lower in t

32 atrial and atrioventricular septal defects, patent ductus arteriosus, bicuspid aortic valve, and coa

33 tif mutation, P62R, had a high prevalence of patent ductus arteriosus but had only mild abnormalities

34 shunts are common after coil embolization of patent ductus arteriosus, but most close spontaneously.

35 disruption of this pathway may contribute to patent ductus arteriosus by affecting the development of

36 facial dysmorphology, osteochondrodysplasia, patent ductus arteriosus, cardiomegaly, pericardial effu

37 ulmonary artery diameter Z score <or=-2.5 or patent ductus arteriosus diameter <or=2 mm was 97% sensi

38 Only one infant required ligation of a patent ductus arteriosus during ECMO.

39 an autosomal dominant trait characterized by patent ductus arteriosus, facial dysmorphism and hand an

40 association was observed between PM(10) and patent ductus arteriosus (for an interquartile range inc

41 2000-2001 to 7.5 per mille in 2012-2013, of patent ductus arteriosus from 1.9 per mille to 4.1 per m

42 Gentamicin clearance was decreased in the patent ductus arteriosus group vs. the control group (40

43 e presence of a haemodynamically significant patent ductus arteriosus had a significant independent i

44 The infants with patent ductus arteriosus had higher values for ventricul

45 Although transcatheter coil occlusion of patent ductus arteriosus has gained popularity, few foll

46 acin for the prevention and treatment of the patent ductus arteriosus have not documented a decrease

47 Rationale: Hemodynamically significant patent ductus arteriosus (hsPDA) in premature infants ha

48 beta, a transcription factor associated with patent ductus arteriosus in humans, was uniquely express

49 l regions (P .05) and with medically managed patent ductus arteriosus in the white matter and deep gr

50 sulted in cardiopulmonary defects, including patent ductus arteriosus, in 30 to 40% of the mice.

51 s), bronchopulmonary dysplasia, surgery, and patent ductus arteriosus interventions (all p < 0.01/p <

52 comorbidities, including perinatal jaundice, patent ductus arteriosus, intraventricular hemorrhage, p

53 In the preterm newborn, a patent ductus arteriosus is in large part a result of th

54 Patent ductus arteriosus ligation among preterm neonates

55 Since the first patent ductus arteriosus ligation by Robert Gross of Bos

56 All 14 premature infants undergoing patent ductus arteriosus ligation in a 1-year period at

57 lar resistance associated with ligation of a patent ductus arteriosus might worsen ventricular perfor

58 nnels might represent novel therapeutics for patent ductus arteriosus, migraine headache, and sepsis;

59 322 courses of gentamicin were administered (patent ductus arteriosus, n = 106; control, n = 216).

60 Patent ductus arteriosus occlusion can be accomplished b

61 children with secundum atrial septal defect, patent ductus arteriosus, or pulmonic stenosis have had

62 Volume of distribution was greater for patent ductus arteriosus patients (0.61 L/kg) than for c

63 Transcatheter closure of the patent ductus arteriosus (PDA) has increasingly been ado

64 results of buttoned device (BD) occlusion of patent ductus arteriosus (PDA) in a large number of pati

65 consensus for the screening and treatment of patent ductus arteriosus (PDA) in extremely preterm infa

66 The management of patent ductus arteriosus (PDA) in preterm infants is con

67 ase inhibitor ibuprofen may be used to treat patent ductus arteriosus (PDA) in preterm infants.

68 Nonsyndromic patent ductus arteriosus (PDA) is a common congenital he

69 Patent ductus arteriosus (PDA) is a common congenital he

70 disrupt pulmonary vascular development, and patent ductus arteriosus (PDA) is a factor potentially a

71 Patent ductus arteriosus (PDA) is a relatively common fo

72 Stenting of the patent ductus arteriosus (PDA) is an established palliat

73 Patent ductus arteriosus (PDA) is associated with increa

74 Observational studies have associated patent ductus arteriosus (PDA) ligation among preterm in

75 7-year-old female with a history of neonatal patent ductus arteriosus (PDA) ligation, left-sided chor

76 Patent ductus arteriosus (PDA) poses a diagnostic and th

77 was performed to determine the frequency of patent ductus arteriosus (PDA) reopening and the factors

78 associated with growth after days 1-8, with patent ductus arteriosus (PDA) showing negative associat

79 A patent ductus arteriosus (PDA) shunt may be a modifiable

80 od flow may undergo palliation with either a patent ductus arteriosus (PDA) stent or a modified Blalo

81 ulmonary blood flow, initial palliation with patent ductus arteriosus (PDA) stent or modified Blalock

82 Transcatheter closure of a moderate to large patent ductus arteriosus (PDA) using conventional techni

83 y systematic echocardiographic screening for patent ductus arteriosus (PDA) vs those who did not unde

84 The patent ductus arteriosus (PDA) was the first congenital

85 Only one atrial septal defect (ASD) and two patent ductus arteriosus (PDA) were missed by DSCT.

86 We found that patent ductus arteriosus (PDA), a common congenital hear

87 inhibitors are commonly used in infants with patent ductus arteriosus (PDA), but the benefit of these

88 ve (BAV), coarctation of the aorta (CoA) and patent ductus arteriosus (PDA).

89 uding aneurysmal dilatation of the aorta and patent ductus arteriosus (PDA).

90 irth, but died prior to postnatal day 3 from patent ductus arteriosus (PDA).

91 ding a locus at 16p for TAAD associated with patent ductus arteriosus (PDA).

92 e to coil occlude the moderate to large size patent ductus arteriosus (PDA).

93 fants receiving indomethacin (INDO) to close patent ductus arteriosus (PDA).

94 trial septal defect (ASD); device closure of patent ductus arteriosus (PDA); pulmonary valvuloplasty;

95 es the use of Gianturco coils to close large patent ductus arteriosus (PDAs) (> or = 3.5 mm) and desc

96 ricular and atrioventricular septal defects; patent ductus arteriosus; pulmonary stenosis; aortic ste

97 tricular leukomalacia, chronic lung disease, patent ductus arteriosus requiring surgery, retinopathy

98 e presence of a haemodynamically significant patent ductus arteriosus results in a deeper impairment

99 Although a persistent patent ductus arteriosus results in diminished cardiac f

100 Medical treatment for patent ductus arteriosus significantly decreased over th

101 atrial septal defects, patent foramen ovale, patent ductus arteriosus, stent placement for pulmonary

102 in dosing should be altered in neonates with patent ductus arteriosus to reflect the impact of higher

103 epsis (AOR, 65.24; 95% CI, 5.70-748.18), and patent ductus arteriosus treatment after 72 hours of lif

104 oarctation, hypoplastic left heart syndrome, patent ductus arteriosus, valvar pulmonary stenosis, tet

105 via imaging (secundum atrial septal defect, patent ductus arteriosus, ventricular septal defect, pul

106 treated cases regardless of whether preterm patent ductus arteriosus was included.

107 f infants who required surgical closure of a patent ductus arteriosus was lower in the budesonide gro

108 ory of asthma, smoking in the household, and patent ductus arteriosus were predictive of wheezing in

109 cts, persistent left superior vena cava, and patent ductus arteriosus, were present in 32% of patient

110 e development of better therapy to close the patent ductus arteriosus, which constitutes approximatel

111 a young age, including congenital mydriasis, patent ductus arteriosus with ligation, dysautonomia, lo

112 Necropsy revealed patent ductus arteriosus with normal intimal thickening

113 ribution was a useful marker for presence of patent ductus arteriosus, with a 92% specificity for pat